Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome

Cardiology (Switzerland)

Volumn 124, Issue 4, 2013, Pages 252-258

  Torngren, Kristina ^a   Öhman, Jenny ^a   Salmi, Hanna ^a   Larsson, Johan ^a   Erlinge, David ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Adenosine; Adenosine diphosphate; Aspirin; Clopidogrel; Endothelium; P2Y12; Peripheral arterial tonometry; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL ARTERIAL FUNCTION; PRIORITY JOURNAL; TONOMETRY; DEMOGRAPHY; FOREARM; LABORATORY TEST;

ACUTE CORONARY SYNDROME; ADENOSINE; ASPIRIN; BLOOD PRESSURE; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84876073045     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000347122     Document Type: Article

References (36)

1. Nawarskas JJ, Clark SM: Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev 2011; 19: 95-100.
2. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James SKatus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
3. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF: Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the onset/offset study. Circulation 2009; 120: 2577-2585.
4. Scirica BM, Cannon CP, Emanuelsson HMichelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin L: The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol 2011; 57: 1908-1916.
5. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A, Cairns R, Cannon CP, Wallentin L: Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011; 32: 2945-2953.
6. van Giezen JJ, Sidaway J, Glaves P, Kirk I, Björkman JA: Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012; 17: 164-172.
7. Ohman J, Kudira R, Albinsson S, Olde B, Erlinge D: Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun 2012; 418: 754-758.
8. Erlinge D, Burnstock G: P2 receptors in cardiovascular regulation and disease. Purinergic Signal 2008; 4: 1-20.
9. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb VascBiol 2002; 23: 168-175.
10. Ross R: Atherosclerosis; an inflammatory disease. N Engl J Med 1999; 340: 115-126.
11. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, Selwyn AP: Close relation of endothelial function in the human coronary and peripheral circulations. JACC 1995; 26: 1235-1241.
12. Kothawade K, Bairey Merz CN: Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. Curr Probl Cardiol 2011; 36: 291-318.
13. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A: Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137-2141.
14. Dhindsa MSS, DeVana AE, Barnesa JN, Sugawaraa JLO, Tanaka H: Inter-relationships among noninvasive measures of postischemic macro- and micro-vascular reactivity. J Appl Physiol 2008; 105: 398-399.
15. Kuvin JT, Mammen A, Mooney P, Alsheikh- Ali AA, Karas RH: Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med 2007; 12: 13-16.
16. Kuvin JT, Patel AR, Sliney KA, Pandian NG, SheffyJ, Schnall RP, Karas RH, Udelson JE: Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003; 146: 168-174.
17. Hamburg NM, Keyes MJ Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA, Benjamin EJ: Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham heart study. Circulation 2008; 117: 2467-2474.
18. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A: Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010; 31: 1142-1148.
19. Nohria A, Gerhard-Herman M, Creager M, Hurley S, Mitra D, Ganz P: Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol 2006; 101: 545-548.
20. Itamar Medical: Assessing Endothelial Function: Overview and Scientific Validation of Endo-PAT2000. 2009.
21. Faizi AK, Kornmo DW, Agewall S: Evaluation of endothelial function using finger plethysmography. Clin Physiol Funct Imaging 2009; 29: 372-375.
22. Schrör K, Siller-Matula JM, Huber K: Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam Clin Pharmacol 2012; 26: 39-46.
23. Warnholtz A, Ostad MA, Velich N, Trautmann C, Schinzel R, Walter U, Munzel T: A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008; 196: 689-695.
24. Ostad MA, Nick E, Paixao-Gatinho V, Schnorbus B, Schiewe R, Tschentscher P, Munzel T, Warnholtz A: Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized Cassandra study. Clin Res Cardiol 2011; 100: 29-36.
25. Heitzer T,Rudolph V,Schwedhelm E,Karstens M,Sydow K,Ortak M,Tschentscher P,Meinertz T,Boger R,Baldus S: Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects Arterioscler Thromb Vasc Biol.2006. 26;1648-1652.
26. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, Tschentscher P, Meinertz T, Boger R, Baldus S: Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006; 26: 1648-1652.
27. Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A, Di Sciascio G: High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J Am Coll Cardiol 2011; 57: 771-778.
28. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
29. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Lim ST, Cannon CP, Katus HA, Wallentin L: Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol 2011; 108: 1542-1546.
30. Gan LM, Wittfeldt A, Emanuelsson H, Nylander S, Andersson M: TCT-162: Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans - a randomised, double-blind, placebo-controlled, crossover, single centre study using transthoracic color Doppler echocardiography. J Am Coll Cardiol 2011; 58:B43.
31. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D: ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 1810-1815.
32. Hogberg C, Svensson H, Gustafsson R, Eyjolfsson A, Erlinge D: The reversible oral P2Y12 antagonist AZD6140 inhibits ADPinduced contractions in murine and human vasculature. Int J Cardiol 2010; 142: 187-192.
33. Tantry US, Gurbel PA: Current options in oral antiplatelet strategies during percutaneous coronary interventions. Rev Cardiovasc Med 2011; 12(suppl 1):S4-S13.
34. Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS: Adjunctive treatment with ticagrelor, but not clopidogrel, added to TPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost 2010; 104: 609-617.
35. Heffernan KS, Patvardhan EA, Kapur NK, Karas RH, Kuvin JT: Peripheral augmentation index as a biomarker of vascular aging: an invasive hemodynamics approach. Eur J Appl Physiol 2012; 112: 2871-2879.
36. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L:Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2010; 122: 1056-1067.